publication . Article . Other literature type . 2017

Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP

Joanne M. Donkers; Benno Zehnder; Gerard J. P. van Westen; Mark J. Kwakkenbos; Adriaan P. IJzerman; Ronald P. J. Oude Elferink; Ulrich Beuers; Stephan Urban; Stan F. J. van de Graaf;
Open Access
  • Published: 10 Nov 2017
  • Country: Netherlands
The sodium taurocholate co-transporting polypeptide (NTCP, SLC10A1) is the main hepatic transporter of conjugated bile acids, and the entry receptor for hepatitis B virus (HBV) and hepatitis delta virus (HDV). Myrcludex B, a synthetic peptide mimicking the NTCP-binding domain of HBV, effectively blocks HBV and HDV infection. In addition, Myrcludex B inhibits NTCP-mediated bile acid uptake, suggesting that also other NTCP inhibitors could potentially be a novel treatment of HBV/HDV infection. This study aims to identify clinically-applied compounds intervening with NTCP-mediated bile acid transport and HBV/HDV infection. 1280 FDA/EMA-approved drugs were screened ...
Medical Subject Headings: digestive systemvirus diseasesviruses
free text keywords: Medicine, R, Science, Q, Article, Multidisciplinary
Funded by
Improving Metabolism via Prolonged Bile Acid Signalling targeting hepatic bile acid uptake to fight metabolic diseases
  • Funder: European Commission (EC)
  • Project Code: 337479
  • Funding stream: FP7 | SP2 | ERC
50 references, page 1 of 4

1. Dawson, P. A., Lan, T. & Rao, A. Bile acid transporters. J Lipid Res 50, 2340-2357, (2009).

2. Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and Dvirus. Elife 1, e00049, (2012).

3. Ni, Y. et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146, 1070-1083, (2014).

4. Seeger, C. & Mason, W. S. Hepatitis B virus biology. Microbiol Mol Biol Rev 64, 51-68 (2000).

5. Alvarado-Mora, M. V., Locarnini, S., Rizzetto, M. & Pinho, J. R. An update on HDV: virology, pathogenesis and treatment. Antivir ehTr 18, 541-548, (2013).

6. Taylor, J. M. Virology of hepatitis D virus. Semin Liver Dis 32, 195-200, (2012).

7. Lempp, F. A., Ni, Y. & Urban, S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol 13, 580-589, (2016).

8. Verrier, E. R. et al. Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. Cell Rep 17, 1357-1368, (2016). [OpenAIRE]

9. Meier, A., Mehrle, S., Weiss, T. S., Mier, W. & Urban, S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to diefrentiated hepatocytes. Hepatology 58, 31-42, (2013).

10. Schieck, A. et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology 58, 43-53, (2013). [OpenAIRE]

11. Gripon, P. et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99, 15655-15660, https://doi. org/10.1073/pnas.232137699 (2002). [OpenAIRE]

12. Schulze, A., Schieck, A., Ni, Y., Mier, W. & Urban, S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 84, 1989-2000, (2010).

13. Bogomolov, P. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol 65, 490-498, (2016).

14. Li, W. & Urban, S. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J Hepatol 64, S32-40, (2016). [OpenAIRE]

15. Lutgehetmann, M. et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55, 685-694, (2012). [OpenAIRE]

50 references, page 1 of 4
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue